Back to Search
Start Over
Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
- Source :
-
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] [Strahlenther Onkol] 2020 Nov; Vol. 196 (11), pp. 1006-1017. Date of Electronic Publication: 2020 May 12. - Publication Year :
- 2020
-
Abstract
- Purpose: To assess the outcome of prostate cancer (PCa) patients diagnosed with oligorecurrent disease and treated with a first and a second PSMA (prostate-specific membrane antigen ligand) PET(positron-emission tomography)-directed radiotherapy (RT).<br />Patients and Methods: Thirty-two patients with oligorecurrent relapse after curative therapy received a first PSMA PET-directed RT of all metastases. After biochemical progression, all patients received a second PSMA PET-directed RT of all metastases. The main outcome parameters were biochemical progression-free survival (bPFS) and androgen deprivation therapy-free survival (ADT-FS). The intervals of BPFS were analyzed separately as follows: the interval from the last day of PSMA PET-directed RT to the first biochemical progression was defined as bPFS&#95;1 and the interval from second PSMA PET-directed RT to further biochemical progression was defined as bPFS&#95;2.<br />Results: The median follow-up duration was 39.5 months (18-60). One out of 32 (3.1%) patients died after 47 months of progressive metastatic prostate cancer (mPCa). All patients showed biochemical responses after the first PSMA PET-directed RT and the median prostate-specific antigen (PSA) level before RT was 1.70 ng/mL (0.2-3.8), which decreased significantly to a median PSA nadir level of 0.39 ng/mL (range <0.07-3.8; p = 0.004). The median PSA level at biochemical progression after the first PSMA PET-directed RT was 2.9 ng/mL (range 0.12-12.80; p = 0.24). Furthermore, the PSA level after the second PSMA PET-directed RT at the last follow-up (0.52 ng/mL, range <0.07-154.0) was not significantly different (p = 0.36) from the median PSA level (1.70 ng/mL, range 0.2-3.8) before the first PSMA PET-directed RT. The median bPFS&#95;1 was 16.0 months after the first PSMA PET-directed RT (95% CI 11.9-19.2) and the median bPFS&#95;2 was significantly shorter at 8.0 months (95% CI 6.3-17.7) after the second PSMA PET-directed RT (p = 0.03; 95% CI 1.9-8.3). Multivariate analysis revealed no significant parameter for bPFS&#95;1, whereas extrapelvic disease was the only significant parameter (p = 0.02, OR 2.3; 95% CI 0.81-4.19) in multivariate analysis for bPFS&#95;2. The median ADT-FS was 31.0 months (95% CI 20.1-41.8) and multivariate analysis showed that patients with bone metastases, compared to patients with only lymph node metastases at first PSMA PET-directed RT, had a significantly higher chance (p = 0.007, OR 4.51; 95% CI 1.8-13.47) of needing ADT at the last follow-up visit.<br />Conclusion: If patients are followed up closely, including PSMA PET scans, a second PSMA PET-directed RT represents a viable treatment option for well-informed and well-selected patients.
- Subjects :
- Adenocarcinoma diagnostic imaging
Adenocarcinoma radiotherapy
Adenocarcinoma surgery
Aged
Bone Neoplasms diagnostic imaging
Bone Neoplasms radiotherapy
Bone Neoplasms secondary
Disease Progression
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Lymphatic Irradiation
Lymphatic Metastasis radiotherapy
Male
Middle Aged
Neoplasm Recurrence, Local diagnostic imaging
Neoplasm Recurrence, Local radiotherapy
Prostatic Neoplasms chemistry
Prostatic Neoplasms diagnostic imaging
Prostatic Neoplasms radiotherapy
Radiation Injuries etiology
Radiotherapy, Image-Guided adverse effects
Adenocarcinoma secondary
Antigens, Neoplasm analysis
Antigens, Surface analysis
Biomarkers, Tumor analysis
Glutamate Carboxypeptidase II analysis
Positron-Emission Tomography
Prostatic Neoplasms surgery
Radiotherapy, Image-Guided methods
Subjects
Details
- Language :
- English
- ISSN :
- 1439-099X
- Volume :
- 196
- Issue :
- 11
- Database :
- MEDLINE
- Journal :
- Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
- Publication Type :
- Academic Journal
- Accession number :
- 32399639
- Full Text :
- https://doi.org/10.1007/s00066-020-01629-5